Activest Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Activest Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.7K	Hold	2,000	–	–	﹤0.01%	487
2026 Q2	$20K	Hold	2,000	–	–	﹤0.01%	444
2026 Q1	$19K	Hold	2,000	–	–	﹤0.01%	534
2025 Q4	$15.6K	Hold	2,000	–	–	﹤0.01%	570
2025 Q3	$15.2K	Hold	2,000	–	–	﹤0.01%	423
2025 Q2	$17.9K	Hold	2,000	–	–	﹤0.01%	344
2025 Q1	$15K	Hold	2,000	–	–	﹤0.01%	332
2024 Q4	$15K	Hold	2,000	–	–	﹤0.01%	277
2024 Q3	$15.2K	Hold	2,000	–	–	﹤0.01%	280
2024 Q2	$12.4K	Buy	+2,000	New	+$11K	﹤0.01%	287

Other funds holding BCRX

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return

Activest Wealth Management's BCRX Position: Q3 2026 in Review

Activest Wealth Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2026 at 2,000 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #487.

Activest Wealth Management first reported a position in BCRX in Q2 2024 and has held it in 10 quarters since. The position peaked at $20K in Q2 2026. 153 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

Activest Wealth Management held 2,000 shares of BioCryst Pharmaceuticals worth $16.7K as of Q3 2026.
Activest Wealth Management left its BioCryst Pharmaceuticals share count unchanged in Q3 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #487 holding.
Activest Wealth Management first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
Activest Wealth Management's BioCryst Pharmaceuticals position peaked at $20K in Q2 2026.
153 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.